EDUR-BRA Study (LACOG 0322-GBOT | D4191R00053): Durvalumab demonstrated efficacy and safety comparable to the CASPIAN trial in Brazilian patients with Extensive-stage small-cell lung cancer
- Brazilian patients treated with first-line durvalumab achieved a median overall survival of 13.4 months.
- The Brazilian cohort, however, was composed of older patients with poorer performance status and a higher frequency of brain metastases compared to the CASPIAN trial.
- These results reinforce the relevance of immunotherapy as the standard of care for ES-SCLC in the real-world setting.
The EDUR-BRA study (LACOG 0322-GBOT | D4191R00053 – NCT06008353) is an observational, multicenter, single-arm analysis conducted across seven healthcare centers in Brazil, which evaluated real-world data of adult patients with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab-based first-line regimens.
Between January and November 2024, a total of 59 patients were included, with a median age of 69 years; 66% were aged ≥65 years. Most patients (88%; N=51) presented with metastatic disease, including brain (20%) and liver (22%) metastases. Nearly all patients (95%) received carboplatin-etoposide in combination with durvalumab, with a median of 8 cycles of immunotherapy administered. The main reason for treatment discontinuation was disease progression (59%).
After a median follow-up of 24.8 months, the median overall survival (OS) was 13.4 months (95% CI: 9.9–15.4), and the median real-world progression-free survival (rwPFS) was 6.9 months (95% CI: 5.1–7.9). Adverse events occurred in 56% of patients, with grade ≥3 events reported in 25%. The most frequent adverse events were fatigue and nausea. Only two patients discontinued durvalumab due to toxicity.
According to the investigators, although the Brazilian patients presented a more challenging clinical profile (older age, poorer performance status, and higher incidence of brain metastases), the efficacy and safety outcomes observed were consistent with those of the phase III CASPIAN trial, which established durvalumab as the standard of care for ES-SCLC.
The study, led by Principal Investigator Dr. Mauro Zukin and co-led by Danilo Lopes, Astrazeneca’s Medical Director, was presented at the World Conference on Lung Cancer (WCLC 2025), held from September 6 to 9, 2025, in Barcelona, Spain, under the title “Assessment of Clinical Characteristics and Outcomes of Brazilian ES-SCLC Patients on First Line Durvalumab + Chemotherapy”.
According to oncologist Dr. Mauro Zukin:
“This study reinforces that durvalumab maintains its benefit in Brazilian patients even outside the clinical trial setting, helping to consolidate real-world evidence in small cell lung cancer. Generating real-world data is essential to understand how therapies perform in different contexts, better reflecting everyday clinical practice and expanding the evidence base to guide therapeutic decisions.”
About LACOG
The Latin American Cooperative Oncology Group (LACOG) is a non-profit organization established in 2009 by physicians dedicated to the advancement of cancer research in Latin America. It is the first multinational cooperative group in the region. It is currently composed of more than 700 physician-investigators, present across 275 institutions in 17 Latin American countries, who work collaboratively to advance the knowledge and practice of oncological treatments.
The group comprises 11 specialty groups in the areas of breast cancer, gynecologic cancers, head and neck cancer, genitourinary cancers, lung cancer, gastrointestinal cancers, neuro-oncology, sarcoma, oncogeriatrics, radiation oncology, and digital health. Its primary objective is to improve cancer treatment outcomes in the region through the conduct of relevant and high-quality clinical and epidemiological research.
Presentation infos:
Date: September 9, 2025
Time: 3:00 PM CEST / UTC +2
Location: Fira de Barcelona Gran Via, Barcelona, Spain
Format: E-Poster (onsite)
Session: EP.13 – Small Cell Lung Cancer and Neuroendocrine Tumors
Poster ID: EP.13.28
Title: Assessment of Clinical Characteristics and Outcomes of Brazilian ES-SCLC Patients on First-Line Durvalumab + Chemotherapy
Presenting Author: Mauro Zukin
You can find more posts featuring LACOG on OncoDaily.